Gilead has a treatment for a coronavirus. Academics want to test it against Covid-19
There’s a compound in Gilead Sciences’ vast library that is remarkably effective against a certain coronavirus in cats. Researchers say it might hold promise for Covid-19 and could even be superior to Gilead’s own remdesivir. Now they’re pressuring the company to find out.
As STAT’s Ed Silverman reports, researchers at the MD Anderson Cancer Center have joined Public Citizen to urge Gilead, the NIH, and the FDA to run a clinical trial on GS-441524, the anti-coronavirus compound. In lab tests, GS-441524 appears to work better than remdesivir against the novel coronavirus, the researchers said, with lower toxicity and an easier manufacturing process.
So far, Gilead has showed no interest in developing GS-441524. The researchers chalk that up to “financial incentives,” pointing out that a key patent for GS-441524 expires several years before the intellectual property behind remdesivir.
Read more.
As STAT’s Ed Silverman reports, researchers at the MD Anderson Cancer Center have joined Public Citizen to urge Gilead, the NIH, and the FDA to run a clinical trial on GS-441524, the anti-coronavirus compound. In lab tests, GS-441524 appears to work better than remdesivir against the novel coronavirus, the researchers said, with lower toxicity and an easier manufacturing process.
So far, Gilead has showed no interest in developing GS-441524. The researchers chalk that up to “financial incentives,” pointing out that a key patent for GS-441524 expires several years before the intellectual property behind remdesivir.
Read more.
.png)
No hay comentarios:
Publicar un comentario